Biomarkers and Surrogate Endpoints: Clinical Research and Applications : Proceedings of the NIH-FDA Conference Held on 15-16 April 1999 in Bethesda, Maryland, USA

Front Cover
Gregory J. Downing
Elsevier, 2000 - Medical - 318 pages
0 Reviews
The potential adaptation of biomarkers as substitutes for clinical endpoints, or surrogate endpoints, in clinical trials has recently taken on new importance. This volume summarizes the proceedings of the first international, multi-disciplinary conference held to discuss this important issue. A historical perspective is provided on the use of biomarkers in drug development, as diagnostic and clinical measuring tools, and in some cases their application as surrogate endpoints in diseases such as AIDS, cancer, and cardiovascular disease. Also included is a review of concepts, terminology, and examples which provide a background for those who are not familiar with the use of biomarkers in drug development and clinical trials.

There is presently no other publication which gives such a unique insight into the current state of understanding of biomarkers for specific disease areas, and the emerging tools and technologies that may be used to discover and evaluate biomarkers. The book also focuses on areas of need or interest in identifying new biomarkers, and key issues for researchers in applying them in drug development and clinical trials.

What people are saying - Write a review

We haven't found any reviews in the usual places.

Related books

Other editions - View all

References from web pages

Clinical Pharmacology & Therapeutics - Biomarkers and ...
Clinical Pharmacology & Therapeutics, the most cited journal publishing primary investigation in pharmacology and pharmacy, is the authoritative, ... clpt/ journal/ v69/ n3/ full/ clpt200113a.html

Technologies used in sequencing of the human. genome are dramatically reshaping the research and. development pathways for drugs, vaccines, and diag- ... biomarkers/ ClinicalParmacology.pdf

Full Text Annual Review of Pharmacology and Toxicology Vol. 41: 347-366 (Volume publication date April 2001) (doi:10.1146/annurev.pharmtox.41.1.347) ... doi/ pdf/ 10.1146/ annurev.pharmtox.41.1.347

Pharmaceutical Medicine - Fulltext: British Journal of Clinical ...
ARTICLE LINKS: PDF (72 K) | References (22) | View full-size inline images. British Journal of Clinical Pharmacology:Volume 59(5)May 2005p 491-494 ... pt/ re/ jpm/ selectreference.htm;jsessionid=HZKTfClGPnMshv7MJzlLhR2WZxCYK82Mpvsj3...

Bert Spilker & Associates
Company Profile. About Us / Who We Serve · Areas of Expertise · Key Services · Expanded Services · Areas of Consulting ... publications.html

NIH Initiatives in Surrogate Endpoints and Endpoint Analysis
Presented. by. Gregory Downing, Ph.D. at the. Nonclinical Studies Subcommittee. of the. Advisory Committee for Pharmaceutical Science. March 9, 2000 ... OHRMS/ DOCKETS/ AC/ 00/ slides/ 3593S1_03_downing.ppt

Biomarkers, Surrogate End Points, and the Acceleration of Drug ...
Clinical Cancer Research. Cancer Epidemiology Biomarkers & Prevention · Molecular Cancer Therapeutics · Molecular Cancer Research · Cancer Prevention ... cgi/ content/ full/ 10/ 11/ 3881

Biomarkers and Surrogate Endpoints: Clinical Research and Applications
Biomarkers and Surrogate Endpoints: Clinical Research and Applications - Elsevier - 0444503161 - 2000 ficha.asp?id=14950& fam=1& subcat=Psiquiatr%EDa+General

Brain Research Bulletin : Change in MRI striatal volumes as a ...
In: gj Downing, Editor, Biomarkers and Surrogate Endpoints: Clinical Research and Applications. Proceedings of NIH-FDA Conference April 15–16, 1999, ... retrieve/ pii/ S0361923006003248

Editors’ view
DOI:10.1111/j.1365-2125.2005.02435.x. British Journal of Clinical Pharmacology. © 2005 Blackwell Publishing Ltd. Br J Clin Pharmacol ... doi/ pdf/ 10.1111/ j.1365-2125.2005.02435.x

Bibliographic information